Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)

NCT07761117 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07761117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07761117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
August 24, 2026
Completion date
September 3, 2029
Enrollment
6,950 (estimated)
Sites
679

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with mildly reduced ejection fraction (hfmref), heart failure with preserved ejection fraction (hfpef)